Volume | 1,170,511 |
|
|||||
News | - | ||||||
Day High | 2.63 | Low High |
|||||
Day Low | 2.27 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Regulus Therapeutics Inc | RGLS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.30 | 2.27 | 2.63 | 2.29 | 2.26 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,792 | 1,170,511 | $ 2.47 | $ 2,890,162 | - | 1.08 - 3.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:57:55 | 14 | $ 2.18 | USD |
Regulus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
45.91M | 20.22M | - | 0 | -30.04M | -1.49 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Regulus Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGLS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.92 | 2.63 | 1.92 | 2.12 | 351,224 | 0.37 | 19.27% |
1 Month | 2.83 | 2.83 | 1.79 | 2.15 | 482,980 | -0.54 | -19.08% |
3 Months | 1.4003 | 3.78 | 1.32 | 2.37 | 3,496,759 | 0.8897 | 63.54% |
6 Months | 1.30 | 3.78 | 1.08 | 2.36 | 1,641,994 | 0.99 | 76.15% |
1 Year | 1.30 | 3.78 | 1.08 | 2.35 | 828,685 | 0.99 | 76.15% |
3 Years | 1.00 | 3.78 | 0.1576 | 1.12 | 1,102,319 | 1.29 | 129.00% |
5 Years | 1.22 | 3.78 | 0.1576 | 1.17 | 1,191,863 | 1.07 | 87.70% |
Regulus Therapeutics Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes. |